" class="no-js "lang="en-US"> Bettina Werle - Medtech Alert
Thursday, September 11, 2025
Bettina Werle

Bettina Werle

About Bettina Werle

Bettina Werle has over 20 years’ experience in creating innovative biotherapeutic solutions for vaccine, diagnostic and therapeutic applications in the field of immunology and infectious diseases, with a global vision from design to development.

With a PhD in cellular and molecular biology and biochemistry from the University of Burgundy, Bettina Werle evolved in various environments from academia to pharmaceutical industries.

She has the ability to enhance the value of research projects via patents and publications and has years of experience working in an R&D setting. Most recently, she worked as CSO and R&D director at Magnisense where she was responsible for developing a new competitive and innovative R&D strategy.

Related Story

Tollys Presents Scientific Data Supporting Preclinical Proof of Concept for TL-532, Its Cancer Immunotherapy Drug Candidate

June 7 2021

Tollys, a biopharmaceutical company developing TL-532, the first synthetic specific agonist of Toll-like Receptor 3 […]